{{chembox
| ImageFile=Proadifen.png
| ImageSize=
| IUPACName=2-Diethylaminoethyl 2,2-diphenylpentanoate
| OtherNames=SKF 525-A
|Section1={{Chembox Identifiers
| CASNo=302-33-0
| PubChem=4910
| ChemSpiderID = 4741
| ChEMBL = 282567
| SMILES = O=C(OCCN(CC)CC)C(c1ccccc1)(c2ccccc2)CCC
| StdInChI = 1S/C23H31NO2/c1-4-17-23(20-13-9-7-10-14-20,21-15-11-8-12-16-21)22(25)26-19-18-24(5-2)6-3/h7-16H,4-6,17-19H2,1-3H3
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = A510CA4CBT
  }}
|Section2={{Chembox Properties
| C=23 | H=31 | N=1 | O=2
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section3={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
}}

'''Proadifen''' (SKF-525A) is a non-selective [[enzyme inhibitor|inhibitor]] of [[cytochrome P450]] [[enzyme]]s, preventing some types of [[drug metabolism]].<ref>{{cite journal | pmid = 14161153 | year = 1964 | last1 = Marshall | first1 = FN | last2 = Williamson | first2 = HE | title = Natruretic Response During Infusion of Beta-Diethylaminoethyl-Diphenylpropyl Acetate Hydrocloride (Skf 525-A) | volume = 143 | pages = 395–400 | journal = The Journal of Pharmacology and Experimental Therapeutics}}</ref> It is also an inhibitor of neuronal [[nitric oxide synthase]] (NOS), CYP-dependent (cytochrome P450-dependent) [[arachidonate]] metabolism, transmembrane calcium influx, and platelet [[thromboxane]] synthesis. Further documented effects include the blockade of ATP-sensitive inward rectifier potassium channel 8 (KIR6.1), and stimulation of [[endothelial cell]] [[prostacyclin]] production.<ref>{{cite web|url=http://www.scbt.com/datasheet-200492-skf-525a-hcl-proadifen.html|title=Santa Cruz Biotech}}</ref>

Proadifen exerts apoptotic/anti-proliferate (tumour suppressing) effects in certain forms of cancer (HT-29 colon adenocarcinoma), believed to be caused by mediation of [[Glycogen synthase kinase 3]] β (GSK-3β). In the same study administration of proadifen was demonstrated to produce time- and dose-dependent [[phosphatidylserine]] externalization, [[caspase-3]] activation and PARP cleavage. Intense upregulation of NAG-1 and ATF3 and downregulation of Mcl-1 and Egr-1 were also observed.<ref>{{cite journal|title=Inhibition of GSK-3β reverses the pro-apoptotic effect of proadifen (SKF-525A) in HT-29 colon adenocarcinoma cells|author= University in Košice, Slovakia; Institute of Biology and Ecology: Rastislav Jendzelovsky, Jan Koval, Jaromír Mikeš, Zuzana Jendzelovska, Jana Plsikova, and Peter Fedoročko|date=June 2012|url=http://www.researchgate.net/publication/225290505_Inhibition_of_GSK-3_reverses_the_pro-apoptotic_effect_of_proadifen_%28SKF-525A%29_in_HT-29_colon_adenocarcinoma_cells|journal=Toxicology in Vitro}}</ref>

Proadifen has been demonstrated to inhibit the [[nicotinic acetylcholine receptor]] (NAChR) and [[muscarinic acetylcholine receptor]] (MAChR) in rats.<ref>{{cite web|url=http://www.scbt.com/datasheet-200492-skf-525a-hcl-proadifen.html|title=Santa Cruz Biotech}}</ref>

==References==
{{Reflist}}


{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Acetylcholine receptor modulators}}
{{Ion channel modulators}}
{{Nitric oxide signaling modulators}}
{{Sigma receptor modulators}}
{{Xenobiotic-sensing receptor modulators}}
}}

[[Category:Valerates]]
[[Category:Cytochrome P450 inhibitors]]


{{pharma-stub}}